Russian Sputnik COVID-19 vaccine ‘will cost less than $10 a dose’The developer of Russia’s COVID-19 vaccine Sputnik V has pledged to make it available for less than $10 Share XRussian Sputnik COVID-19 vaccine ‘will cost less than $10 a dose’https://pharmaphorum.com/news/russian-sputnik-covid-19-vaccine-will-cost-less-than-10-a-dose/
Russia claims 92% efficacy for Sputnik COVID-19 shotIn the second positive piece of COVID-19 vaccine news in a week, Russia’s Sputnik V candidate has been Share XRussia claims 92% efficacy for Sputnik COVID-19 shothttps://pharmaphorum.com/news/russia-claims-92-efficacy-for-sputnik-covid-19-shot/
Russia’s COVID-19 vaccine filed with WHO, as MHRA reviews Moderna shotRussia’s sovereign wealth fund has filed applications with the World Health Organization (WHO) that if approved could see Share XRussia’s COVID-19 vaccine filed with WHO, as MHRA reviews Moderna shothttps://pharmaphorum.com/market-access-2/russias-sputnik-v-covid-19-shot-filed-with-who/
Sanofi preps trials of second COVID-19 shot, as Russia approves anotherSanofi will shortly start human trials of a second coronavirus vaccine, developed with US biotech Translate Bio, after Share XSanofi preps trials of second COVID-19 shot, as Russia approves anotherhttps://pharmaphorum.com/news/sanofi-preps-trials-of-second-covid-19-shot-as-russia-approves-another/
Takeda nets $660m from product selloff to Germany’s StadaTakeda has divested another block of products it views as lying outside its main focus, selling various drugs Share XTakeda nets $660m from product selloff to Germany’s Stadahttps://pharmaphorum.com/news/takeda-nets-660m-from-product-selloff-to-germanys-stada/
Six factors shaping healthcare in emerging marketsThe factors shaping the healthcare landscape in emerging markets. Share XSix factors shaping healthcare in emerging marketshttps://pharmaphorum.com/views-and-analysis/healthcare-emerging-markets/